To evaluate the acute therapeutic effect of type II, a severe acquired HemA monkey bleeding model was developed using a sheep anti-human FVIII polyclonal antibody to induce HemA followed by anti-APC mAb treatment and tail-vein injury. Here, F8 is linked to hemophilia A.